CN1422640A - Medicine for treating lung cancer and its preparation method - Google Patents
Medicine for treating lung cancer and its preparation method Download PDFInfo
- Publication number
- CN1422640A CN1422640A CN 01139792 CN01139792A CN1422640A CN 1422640 A CN1422640 A CN 1422640A CN 01139792 CN01139792 CN 01139792 CN 01139792 A CN01139792 A CN 01139792A CN 1422640 A CN1422640 A CN 1422640A
- Authority
- CN
- China
- Prior art keywords
- fructus
- lung cancer
- cancer drugs
- bletillae
- parched
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The Chinese medicine for curing pulmonary carconoma with obvious therpautic effect is made from 11 Chinese medicinal materials of ovate atratylodes root, schisandra berry, bletilla tuber, Zhijiang fritillaria, mulberry root bark and others through the processes of water extraction and alcohol extraction separately according to different property of every Chinese medicinal material, and can be made into various dosage forms.
Description
The present invention relates to a kind of treatment lung cancer drugs.Be the Chinese patent medicine of feedstock production specifically, the invention still further relates to the preparation method of this medicine with Chinese medicine.
Pulmonary carcinoma is common malignancy, and its sickness rate occupies the 1st in the big city, and the trend that increases is year by year arranged in recent years, about 70% had been middle and advanced stage when pulmonary carcinoma was gone to a doctor, and lost the surgical engine meeting, needed chemicotherapy, though chemicotherapy development in recent years is very fast, median survival interval does not obviously improve.The part patient can not accept and/or be reluctant to accept chemicotherapy simultaneously, is ready to accept Chinese medicine, and mass data prompting treatment middle and advanced stage tumor Chinese medicine obviously is better than chemicotherapy in the quality of making the life better, prolongation aspect life cycle.
Though the medicine of some treatment tumors is arranged at present, and not fairly obvious to the pulmonary carcinoma curative effect, flat lung oral liquid is to formulate prescription according to the core pathogenesis deficiency of YIN pyretic toxicity of medium and advanced lung cancer.
The object of the present invention is to provide a kind of have press down tumor, raise immunity, the quality of making the life better, prolong the lung cancer therapy medicine of the effect of life cycle.
Another object of the present invention provides the lung cancer therapy medicine--the preparation method of flat lung oral liquid.
Solution of the present invention is based on understanding and the Therapeutic Principle of motherland's medical science to lung cancer morbidity mechanism, achieve with reference to modern pharmacological research, from motherland's medicine treasure-house, filter out the Chinese medicine of YIN nourishing lung heat clearing, anticancer dispersing, press the tcm theory prescription, effective component extracting makes that its performance is anticancer, raise immunity, the quality of making the life better, and prolongs effect life cycle.
Medicine of the present invention is made by following component: (consumption is a weight portion)
Rhizoma Atractylodis Macrocephalae 6-15 Fructus Schisandrae Chinensis 6-15 Pseudobulbus Bletillae (Rhizoma Bletillae) 15-25 Bulbus Fritillariae Thunbergii 15-25
Cortex Mori 8-15 Herba Houttuyniae 8-15 Endothelium Corneum Gigeriae Galli (parched) 8-15 Fructus Akebiae 8-15
Fructus Trichosanthis 15-25 Semen Raphani 8-15 Herba Hedyotidis Diffusae 30-40
Formula optimization weight (part) ratio range of preparation medicine of the present invention is:
Rhizoma Atractylodis Macrocephalae 8-12 Fructus Schisandrae Chinensis 8-12 Pseudobulbus Bletillae (Rhizoma Bletillae) 18-22 Bulbus Fritillariae Thunbergii 18-22 Cortex Mori 8-12
Herba Houttuyniae 8-12 Endothelium Corneum Gigeriae Galli (parched) 8-12 Fructus Akebiae 8-12 Fructus Trichosanthis 18-22 Semen Raphani 8-12
Herba Hedyotidis Diffusae 30-35
The optimum weight of medicine of the present invention (part) proportioning is:
The Rhizoma Atractylodis Macrocephalae 10 Fructus Schisandrae Chinensis 10 Pseudobulbus Bletillae (Rhizoma Bletillae)s 20 Bulbus Fritillariae Thunbergiis 20 Cortex Mori 10 Herba Houttuyniae 10
Endothelium Corneum Gigeriae Galli (parched) 10 Fructus Akebiaes 10 Fructus Trichosanthis 20 Semen Raphanis 10 Herba Hedyotidis Diffusaes 30
Can be made into various dosage forms.
Embodiment:
Rhizoma Atractylodis Macrocephalae 10g Fructus Schisandrae Chinensis 10g Pseudobulbus Bletillae (Rhizoma Bletillae) 20g Bulbus Fritillariae Thunbergii 20g Cortex Mori 10g Herba Houttuyniae 10g
Endothelium Corneum Gigeriae Galli (parched) 10g Fructus Akebiae 10g Fructus Trichosanthis 20g Semen Raphani 10g Herba Hedyotidis Diffusae 30g
Preparation method:
(1) get the Rhizoma Atractylodis Macrocephalae, Fructus Schisandrae Chinensis, the Pseudobulbus Bletillae (Rhizoma Bletillae), Bulbus Fritillariae Thunbergii, Fructus Trichosanthis, Semen Raphani, Herba Hedyotidis Diffusae water and carry 2 times, each 2h filters.
(2) get Cortex Mori, Herba Houttuyniae, Endothelium Corneum Gigeriae Galli (parched), Fructus Akebiae and add 95% ethanol, to containing alcohol amount 55%, extract, be recycled to when not having alcohol, it is an amount of to add water, heat cold preservation 24 hours, recovery 30 minutes.
(3) 1,2 extracts are mixed, filter, add stevioside, transfer pH value to 5 promptly, in the packing 10ml ampoule, make oral liquid.
Clinical drug of the present invention uses the result to show that following advantage is arranged:
1. the present invention selects conventional Chinese medicine for use, and medicine source abundance, each component are that pharmacopeia is contained, meets the pharmaceutical control law regulation.
2. the present invention is an oral liquid, need not decoct medicine mildly bitter flavor, taking convenience.
3. both can use separately, can cooperate chemicotherapy again, can potentiation, can alleviate the chemicotherapy toxicity again, the quality of making the life better prolongs life cycle.
4. inexpensive
For showing the therapeutic effect of medicine of the present invention to III-IV phase primary lung cancer, the present invention is through the clinical observation of 90 routine patients with lung cancer systems, be divided into three groups of patients at random, blank group, flat lung oral liquid group, ZHENQI FUZHENG JIAONANG group, every group 30 example, three groups of patient's age, sex, histological type, clinical stages, Ka Shi scoring no significant difference that distributes.The flat lung oral liquid group 20ml that at every turn takes medicine, every day three times; The ZHENQI FUZHENG JIAONANG group is taken medicine 6 at every turn, observes February altogether every day 2 times, and be 1 course of treatment.
Clinical test results such as following table:
As can be seen from Table 1, flat lung oral liquid group cancer dwindles degree and the blank group has significant difference, a little more than the ZHENQI FUZHENG JIAONANG group, stronger cancer suppressing action is arranged.
Table 2 data show that flat lung oral liquid group treatment back patient obviously improves before the treatment quality of life.
Table 3 Notes of Key Data, before treat with treat the back cardinal symptom to recently, flat lung oral liquid improves clinical symptoms and has effect preferably, cough, cough up phlegm, out of breath, spitting of blood, chest pain take on 6 groups of symptoms of acid and spiritlessness and weakness and to compare with other two groups that all there were significant differences (P＜0.05).
As can be seen from Table 4, flat lung oral liquid Th
1/ Th
2Obviously improve before the treatment treatment back, illustrates that it has the raising immunity function.
Other: routine blood test, hepatic and renal function, the electrocardiogram of three groups of patient treatment front and back have no significant change.
Table 1 tumor kitchen range situation of change group example number CR PR NC PD blank group 30 00 12 18 flat lung oral liquid group 30 03 20 7 ZHENQI FUZHENG JIAONANG groups 30 00 19 11
P value blank group 30 39.8 ± 5.7 38.4 ± 8.4 0.165 flat lung oral liquid groups 30 39.4 ± 6.7 42.6 ± 9.2 0.006 ZHENQI FUZHENG JIAONANG group 30 42.2 ± 7.0 43.2 ± 8.5 0.316 after the treatment before the comparison group example number treatment that QOL quality of life mark before and after table 2 treatment
The comparison of three groups of treatment backs of table 3 doing well,improving situation
Respectively organize Th before and after table 4 treatment
1/ Th
2P value blank group 30 1.2 ± 0.9 1.3 ± 0.6 0.593 flat lung oral liquid groups 30 1.0 ± 0.8 2.0 ± 2.9 0.027 ZHENQI FUZHENG JIAONANG group 30 1.1 ± 1.1 1.3 ± 1.0 0.517, treatment back before the situation group example number treatment that ratio changes
Claims (6)
1. treat lung cancer drugs for one kind, it is characterized in that it is the medicament of being made by the raw material of following weight parts:
Rhizoma Atractylodis Macrocephalae 6-15 Fructus Schisandrae Chinensis 6-15 Pseudobulbus Bletillae (Rhizoma Bletillae) 15-25 Bulbus Fritillariae Thunbergii 15-25
Cortex Mori 8-15 Herba Houttuyniae 8-15 Endothelium Corneum Gigeriae Galli (parched) 8-15 Fructus Akebiae 8-15
Fructus Trichosanthis 15-25 Semen Raphani 8-15 Herba Hedyotidis Diffusae 30-40
2. treatment lung cancer drugs according to claim 1, wherein the weight portion of each raw material is:
Rhizoma Atractylodis Macrocephalae 8-12 Fructus Schisandrae Chinensis 8-12 Pseudobulbus Bletillae (Rhizoma Bletillae) 18-22 Bulbus Fritillariae Thunbergii 18-22
Cortex Mori 8-12 Herba Houttuyniae 8-12 Endothelium Corneum Gigeriae Galli (parched) 8-12 Fructus Akebiae 8-12
Fructus Trichosanthis 18-22 Semen Raphani 28-12 Herba Hedyotidis Diffusae 30-40
3. treatment lung cancer drugs according to claim 1, wherein the weight portion of each raw material is:
The Rhizoma Atractylodis Macrocephalae 10 Fructus Schisandrae Chinensis 10 Pseudobulbus Bletillae (Rhizoma Bletillae)s 20 Bulbus Fritillariae Thunbergiis 20
Cortex Mori 10 Herba Houttuyniae 10 Endothelium Corneum Gigeriae Galli (parched)s 10 Fructus Akebiaes 10
Fructus Trichosanthis 20 Semen Raphanis 10 Herba Hedyotidis Diffusaes 30
4. according to claim 1,2 or 3 described treatment lung cancer drugs, it is characterized in that said medicament is a said dosage form on any pharmaceutics.
5. treatment lung cancer drugs according to claim 4 is characterized in that said medicament is an oral liquid.
6. the preparation method of the described treatment lung cancer drugs of claim 5 is characterized in that getting the Rhizoma Atractylodis Macrocephalae, Fructus Schisandrae Chinensis, the Pseudobulbus Bletillae (Rhizoma Bletillae), Bulbus Fritillariae Thunbergii, Fructus Trichosanthis, Semen Raphani, Herba Hedyotidis Diffusae water and carries 2 times, filters; Get Cortex Mori, Herba Houttuyniae, Endothelium Corneum Gigeriae Galli (parched), Fructus Akebiae, add 95% ethanol, to containing alcohol amount 55%, extract, being recycled to does not have the alcohol flavor, and it is an amount of to add water, heats 30 minutes, and cold preservation 24 hours is reclaimed.With water extract, ethanol extract hybrid filtering, add stevioside, transfer pH value to 5 promptly.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 01139792 CN1422640A (en) | 2001-12-05 | 2001-12-05 | Medicine for treating lung cancer and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 01139792 CN1422640A (en) | 2001-12-05 | 2001-12-05 | Medicine for treating lung cancer and its preparation method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1422640A true CN1422640A (en) | 2003-06-11 |
Family
ID=4675418
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 01139792 Pending CN1422640A (en) | 2001-12-05 | 2001-12-05 | Medicine for treating lung cancer and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1422640A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103432401A (en) * | 2013-08-20 | 2013-12-11 | 梁世杰 | Traditional Chinese medicine powder prepared from three flowers, five seeds and six whites for treating lung cancer |
-
2001
- 2001-12-05 CN CN 01139792 patent/CN1422640A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103432401A (en) * | 2013-08-20 | 2013-12-11 | 梁世杰 | Traditional Chinese medicine powder prepared from three flowers, five seeds and six whites for treating lung cancer |
| CN103432401B (en) * | 2013-08-20 | 2015-04-22 | 梁世杰 | Traditional Chinese medicine powder prepared from three flowers, five seeds and six whites for treating lung cancer |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101095736B (en) | Chinese traditional medicine composition for treating acute and chronic pharyngitis, tonsillitis and method of making the same | |
| CN101947284B (en) | Traditional Chinese medicinal composition for treating diabetes and preparation method thereof | |
| CN111686147A (en) | Eucommia ulmoides extract and application thereof in treating osteoporosis | |
| CN1814162A (en) | Pulse-promoting large-volume injecta and preparing method | |
| CN1181877C (en) | Medicine for curing diabetes and nephrosis and its preparing method | |
| CN1320896C (en) | Dangshen astragalus composition for regulating immunity and its preparation method | |
| CN1895593A (en) | Medicine for treating acne and its preparation | |
| CN1422640A (en) | Medicine for treating lung cancer and its preparation method | |
| CN103393938B (en) | Traditional Chinese medicine composition for reducing blood sugar | |
| CN101062292A (en) | Medicine for treating cancer and preventing lung cancer and preparing method thereof | |
| CN1284548C (en) | Preparation technology of supplementing kind capsule | |
| CN1081042C (en) | Traditional Chinese medicinal composition for stopping drug taking and preparation process thereof | |
| CN1692922A (en) | Medicine composite used for lowering blood-sugar, prepn. method and use thereof | |
| CN1178890C (en) | Method for extracting hypericin from Hypericum perforatum and medicine made up using hypericin as main composition | |
| CN1899385A (en) | Process for preparing Chinese medicine compound injection for treating chronic renal failure and use | |
| CN103520684A (en) | Traditional Chinese medicine compound for reducing blood sugar | |
| CN108686094A (en) | A kind of Traditional Chinese medicine for decreasing blood sugar and preparation method thereof | |
| CN1228065C (en) | Medication for chronic renal failure | |
| CN102670922A (en) | Chinese medicine oral fluid with seeds of feather cockscomb for treating diarrhea and preparing method thereof | |
| CN108079113A (en) | A kind of pharmaceutical composition for treating the postpartum deficiency of blood and preparation method thereof | |
| CN100493537C (en) | Traditional Chinese medicinal preparation for treating phthisis and its preparation method | |
| CN1058882C (en) | Oral liquor for treating tumour and disease of liver, and preparation method thereof | |
| CN1201775C (en) | Medicine for treating insomnia-sleeping particle and preparation thereof | |
| CN1151834C (en) | Pure Chinese medicine for giving up drugs and its preparation method | |
| CN100341543C (en) | Kidney-tonifying brain-invigorating medicine and preparation process thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |